ibritumomab tiuxetan

Home
Ligands
ibritumomab tiuxetan

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®

ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))

Compound class: Antibody

Comment: A monoclonal antibody used as a radioimmunotherapy treatment.

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. (1999) Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol, 15 (5): 1017-25. [PMID:10536187]

References

1. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. (1999)
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Int J Oncol, 15 (5): 1017-25. [PMID:10536187]